

Remix Therapeutics Collaboration Agreement with Janssen Pharmaceutica NV

Client News

February 17, 2022

Gunderson Dettmer represented Remix Therapeutics, a Massachusetts-based biotech company, in its collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration will center on advancing small molecule therapeutics using the REMaster drug discovery platform to modulate RNA processing.

In the [announcement of the agreement](#), co-founder and CEO of Remix Therapeutics Peter Smith Ph.D. said, “We look forward to collaborating with this innovative team. Janssen is an ideal strategic partner for our REMaster platform. This collaboration further validates the therapeutic potential of our proprietary REMaster drug discovery platform and provides additional resources to translate our cutting-edge science into new medicines.”

The Gunderson deal team was led by Tim Ehrlich and included Aliya Sanders and Alice Kuo.

Related People





Timothy H. Ehrlich
PARTNER
P +1 617 648 9399



Aliya J. Sanders
PARTNER
P +1 212 430 3172

Related Services

Strategic Transactions & Licensing

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad